Time To Efficacy and Onset Of Action Of Linezolid

This study has been completed.

First Received: September 2, 2005 Last Updated: August 10, 2007 History of Changes

Sponsor:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00147511

Purpose

To assess the onset of action of linezolid

Condition	Intervention	Phase
Gram-Positive Bacterial Infections Skin and Connective Tissue Diseases	Drug: linezolid	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:	Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections

Resource links provided by NLM:

MedlinePlus related topics: Bacterial Infections Connective Tissue Disorders

Drug Information available for: Linezolid

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

Time to defervescence

Secondary Outcome Measures:

Reduction of CRP levels Reduction of leucocyte count

Estimated Enrollment:	120
Study Start Date:	June 2003
Estimated Study Completion Date:	June 2005

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

suspected grampositive infection
fever > 38 C

Exclusion Criteria:

Infections to be treated successfully by surgical procedures

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00147511

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

Link to ClinicalStudyResults.org posting This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	OXAA-0026-162
Study First Received:	September 2, 2005
Last Updated:	August 10, 2007
ClinicalTrials.gov Identifier:	NCT00147511 History of Changes
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:

Bacterial Infections
Protein Synthesis Inhibitors
Anti-Infective Agents
Communicable Diseases
Gram-Positive Bacterial Infections
Molecular Mechanisms of Pharmacological Action

Therapeutic Uses
Connective Tissue Diseases
Enzyme Inhibitors
Infection
Linezolid
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010